Pfizer's plan to quadruple US prices for its COVID-19 vaccine next year is beyond Wall Street's expectations and will spur its revenue for years despite weaker than anticipated demand for the new booster shot so far, analysts said. www.reuters.com/business/healthcare-pharmaceuticals/pfizer-covid-vaccine-price-hike-seen-giving-revenue-boost-years-2022-10-21/? The...

The COVID-19 Response Mechanism (C19RM) of the Global Fund has initiated the process to award US$320 million to various countries worldwide. Since December 2022, the Fund has awarded US$547 million in additional funding to 40 countries. The latest tranche...